"Real women are being silenced and gagged in the process."
FOR IMMEDIATE RELEASE
Thursday | December 18, 2014
CONTACT: Jay Hobbs, Director of Communications and Marketing This email address is being protected from spambots. You need JavaScript enabled to view it.
COLUMBUS, OH – An article first posted Dec. 5 on Vocativ.com before it was picked up at Slate.com and The Daily Mail, among others, calls into question both the demand and medical research behind a treatment designed to reverse the effects of Mifepristone, developed by Dr. George Delgado, M.D., F.A.A.F.P.
Dr. Delgado, who sits on Heartbeat International's Medical Advisory Board, is medical director of Culture of Life Family Health Care and founder of AbortionPillReversal.com, which has built a network of 226 pro-life OB-GYNs who are prepared to provide an early dose of supplemental progesterone to block the effects of Mifepristone—the first of two pills administered in the RU-486 regimen.
"We are grateful for Dr. Delgado's work," Heartbeat International President Peggy Hartshorn, Ph.D., said. "It is a shame to see his good work besmirched by agenda-driven writers, determined to grow the business of abortion.
"The tragic thing is that real women who have either been helped by this treatment or wish that they had been, are being silenced and gagged in the process," Hartshorn said. "Pregnancy help organizations like Dr. Delgado's offer each and every woman the true compassion, support, and choice she deserves."
The articles—released over two years after Heartbeat International reported the site's launch and first distributed a webinar on the procedure through Heartbeat Academy—cite the small sample size of women included in an initial peer-reviewed 2012 report published by Dr. Delgado.
Dr. Delgado's team is currently reviewing its cases from the time of the initial report—which included 28 contacts and four births following ingestion of Mifepristone from May to December 2012.
Neither Dr. Delgado nor his team have been contacted by reporters linked to the recent articles.
